Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores

References

• Fisher SG, Fisher RI. The epidemiology of non-Hodgkin's lymphoma. Oncogene 2004;23:6524–6534.
   PubMed Web of Science ®Google Scholar
• Mitterlechner T, Fiegl M, Muhlbock H, et al Epidemiology of non-Hodgkin lymphomas in Tyrol/Austria from 1991 to 2000. J Clin Pathol 2006;59:48–55.
   PubMed Web of Science ®Google Scholar
• Stein H, Warnke RA, Chan WC, et al Diffuse large B-cell lymphoma, not otherwise specified. In: Swerdlow SH, Campo E, Harris NL, et al, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: WHO Press; 2008. pp 233–237.
   Google Scholar
• Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene 2007;26:3603–3613.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Donaldson J, Chhanabhai M, et al Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027–5033.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, et al CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncology 2006;7:379–391.
   PubMed Web of Science ®Google Scholar
• Shipp MA, Harrington DP, Anderson JR, et al A predictive model for aggressive NHL: the international non-Hodgkin's lymphoma prognostic factors project. N Engl J Med 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Berry B, Chhanabhai M, et al The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857–1861.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Pileri SA, Went P, Ascani S, et al Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification. Histopathology 2002;41:482–509.
   PubMed Web of Science ®Google Scholar
• Shipp MA, Ross KN, Tamayo P, et al Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68–74.
   PubMed Web of Science ®Google Scholar
• de Leval L, Harris NL. Variability in immunophenotype in diffuse large B-cell lymphoma and its clinical relevance. Histopathology 2003;43:509–528.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Staudt LM. Gene expression profiling of diffuse large B-cell lymphoma. Leuk Lymphoma 2003;44(Suppl 3):41–47.
   Web of Science ®Google Scholar
• Wright G, Tan B, Rosenwald A, et al A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA 2003;100:9991–9996.
   PubMed Web of Science ®Google Scholar
• Lossos IS. Molecular pathogenesis of diffuse large B-cell lymphoma. J Clin Oncol 2005;23:6351–6357.
   PubMed Web of Science ®Google Scholar
• Morgensztern D, Lossos IS. Molecular prognostic factors in diffuse large B-cell lymphoma. Curr Treat Options Oncol 2005;6:269–277.
   PubMedGoogle Scholar
• de Paepe P, de Wolf-Peeters C. Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities. Leukemia 2007;21:37–43.
   PubMed Web of Science ®Google Scholar
• Barrans SL, Carter I, Owen R, et al Germinal center phenotype and bcl-2 expression combined with the International Prognostic index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002;99:1136–1143.
   PubMed Web of Science ®Google Scholar
• Colomo L, Lopez-Guillermo A, Perales M, et al Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003;101:78–84.
   PubMed Web of Science ®Google Scholar
• Tzankov A, Pehrs AC, Zimpfer A, et al Prognostic significance of CD44 expression in diffuse large B-cell lymphoma of activated and germinal centre B-cell-like types: a tissue microarray analysis of 90 cases. J Clin Pathol 2003;56:747–752.
   PubMed Web of Science ®Google Scholar
• Chang CC, McClintock S, Cleveland RP, et al Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 2004;28:464–470.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275–282.
   PubMed Web of Science ®Google Scholar
• Saez AI, Saez AJ, Artiga MJ, et al Building an outcome predictor model for diffuse large B-cell lymphoma. Am J Pathol 2004;164:613–622.
   PubMed Web of Science ®Google Scholar
• Berglund M, Thunberg U, Amini RM, et al Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol 2005;18:1113–1120.
   PubMed Web of Science ®Google Scholar
• Muris JJ, Meijer CJ, Vos W, et al Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B-cell lymphoma. J Pathol 2006;208:714–723.
   PubMed Web of Science ®Google Scholar
• Oh YH, Park CK. Prognostic evaluation of nodal diffuse large B-cell lymphoma by immunohistochemical profiles with emphasis on CD138 expression as a poor prognostic factor. J Korean Med Sci 2006;21:397–405.
   PubMed Web of Science ®Google Scholar
• Tzankov A, Gschwendtner A, Augustin F, et al Diffuse large B-cell lymphoma with overexpression of cyclin E substantiates poor standard treatment response and inferior outcome. Clin Cancer Res 2006;12:2125–2132.
   PubMed Web of Science ®Google Scholar
• van Imhoff GW, Boerma EJ, van der Holt B, et al Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clini Oncol 2006;24:4135–4142.
   PubMed Web of Science ®Google Scholar
• Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA, Dirnhofer S. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 2008;93:193–200.
   PubMed Web of Science ®Google Scholar
• Gascoyne RD. Emerging prognostic factors in diffuse large B-cell lymphoma. Curr Opin Oncol 2004;16:436–441.
   PubMed Web of Science ®Google Scholar
• Sehn LH. Optimal use of prognostic factors in non-Hodgkin lymphoma. Hematology/the Education Program of the American Society of Hematology. Am Soc Hematol Educ Program 2006;295–302.
   PubMedGoogle Scholar
• de Jong D, Rosenwald A, Chhanabhai M, et al Lunenburg lymphoma biomarker consortium. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications – a study from the Lunenburg lymphoma biomarker consortium. J Clin Oncol 2007;25:805–812.
   PubMed Web of Science ®Google Scholar
• Gascoyne RD, Adomat SA, Krajewski S, et al Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997;90:244–251.
   PubMed Web of Science ®Google Scholar
• Rantanen S, Monni O, Joensuu H, et al Causes and consequences of bcl-2 overexpression in diffuse large B-cell lymphoma. Leuk Lymphoma 2001;42:1089–1098.
   PubMed Web of Science ®Google Scholar
• Iqbal J, Neppalli VT, Wright G, et al BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 2006;24:961–968.
   PubMed Web of Science ®Google Scholar
• Lossos IS, Jones C, Warnke R, et al Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood 2001;98:945–951.
   PubMed Web of Science ®Google Scholar
• Braaten K, Betensky R, de Leval L, et al Bcl-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res 2003;9:1063–1069.
   PubMed Web of Science ®Google Scholar
• Ohshima K, Kawasaki C, Muta K, et al CD10 and Bcl10 expression in diffuse large B-cell lymphoma: CD10 is a marker of improved prognosis. Histopathology 2001;39:156–162.
   PubMed Web of Science ®Google Scholar
• Uherova P, Ross C, Schnitzer B, et al The clinical significance of CD10 antigen expression in diffuse large B-cell lymphomas. Am J Clin Pathol 2001;115:582–588.
   PubMed Web of Science ®Google Scholar
• Fabiani B, Delmer A, Lepage E, et al CD10 expression in diffuse large B-cell lymphomas does not influence survival. Virchows Archiv 2004;445:545–551.
   PubMed Web of Science ®Google Scholar
• Erlanson M, Portin C, Linderholm B, et al Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas-prognostic implications. Blood 1998;92:770–777.
   PubMed Web of Science ®Google Scholar
• Barrans SL, Fenton JA, Banham A, et al Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood 2004;104:2933–2935.
   PubMed Web of Science ®Google Scholar
• Banham AH, Connors JM, Brown PJ, et al Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin Cancer Res 2005;11:1065–1072.
   PubMed Web of Science ®Google Scholar
• Natkunam Y, Warnke R, Montgomery K, et al Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry. Mod Pathol 2001;14:686–694.
   PubMed Web of Science ®Google Scholar
• de Azambuja E, Cardoso F, de Castro G Jr, et al Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 2007;96:1504–1513.
   PubMed Web of Science ®Google Scholar
• McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. REporting recommendations for tumour MARKer prognostic studies (REMARK). Eur J Cancer 2005;41:1690–1696.
   PubMed Web of Science ®Google Scholar
• Hermanek P. Prognostic factor research in oncology. J Clin Epidemiol 1999;52:371–374.
   PubMed Web of Science ®Google Scholar
• Altman DG. Systematic reviews of evaluations of prognostic variables. Br Med J 2001;323:224–228.
   PubMed Web of Science ®Google Scholar
• Concato J. Challenges in prognostic analysis. Cancer 2001;91(8 Suppl):1607–1614.
   PubMed Web of Science ®Google Scholar
• Riley RD, Abrams KR, Sutton AJ, et al Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future. Br J Cancer 2003;88:1191–1198.
   PubMed Web of Science ®Google Scholar
• Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 2004;4:309–314.
   PubMed Web of Science ®Google Scholar
• Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 2004;159:882–890.
   PubMed Web of Science ®Google Scholar
• Mallett S, Deeks JJ, Halligan S, Hopewell S, Cornelius V, Altman DG. Systematic reviews of diagnostic tests in cancer: review of methods and reporting. Br Med J 2006;333:413.
   PubMed Web of Science ®Google Scholar
• Ransohoff DF. How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. J Clin Epidemiol 2007;60:1205–1219.
   PubMed Web of Science ®Google Scholar
• Ransohoff DF. Promises and limitations of biomarkers. Recent Results Cancer Res 2009;181:55–59.
   PubMedGoogle Scholar
• van Spronsen DJ, Vrints LW, Hofstra G, Crommelin MA, Coebergh JW, Breed WP. Disappearance of prognostic significance of histopathological grading of nodular sclerosing Hodgkin's disease for unselected patients, 1972–1992. Br J Haematol 1996;96:322–327.
   Web of Science ®Google Scholar
• Mounier N, Briere J, Gisselbrecht C, et al Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003;101:4279–4284.
   PubMed Web of Science ®Google Scholar
• Atkins D, Reiffen KA, Tegtmeier CL, et al Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 2004;52:893–901.
   PubMed Web of Science ®Google Scholar
• Zlobec I, Terracciano L, Jass JR, et al Value of staining intensity in the interpretation of immunohistochemistry for tumor markers in colorectal cancer. Virchows Archiv 2007;451:763–769.
   PubMed Web of Science ®Google Scholar
• Zu Y, Steinberg SM, Campo E, Hans CP, et al Pathology panel of the lymphoma/leukemia molecular profiling project. Validation of tissue microarray immunohistochemistry staining and interpretation in diffuse large B-cell lymphoma. Leuk Lymphoma 2005;46:693–701.
   PubMed Web of Science ®Google Scholar
• Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Der Pathologe 1987;8:138–140.
   PubMed Web of Science ®Google Scholar
• Tzankov A, Went P, Zimpfer A, et al Tissue microarray technology: principles, pitfalls and perspectives – lessons learned from hematological malignancies. Exp Gerontol 2005;40:737–744.
   PubMed Web of Science ®Google Scholar
• Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrica 1951;16:297–334.
   Web of Science ®Google Scholar
• MacLennan RN. Interrater reliability with SPSS for Windows 5.0. Am Stat 1993;47:292–296.
   Web of Science ®Google Scholar
• Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307–310.
   PubMed Web of Science ®Google Scholar
• Lusted LB. Decision-making studies in patient management. N Engl J Med 1971;284:416–424.
   PubMed Web of Science ®Google Scholar
• Lusted LB. Signal detectability and medical decision-making. Science 1971;171:1217–1219.
   PubMed Web of Science ®Google Scholar
• Coffin M, Sukhatme S. Receiver operating characteristic studies and measurement errors. Biometrics 1997;53:823–837.
   PubMed Web of Science ®Google Scholar
• Cheung R, Altschuler MD, D'Amico AV, Malkowicz SB, Wein AJ, Whittington R. Using the receiver operating characteristic curve to select pretreatment and pathologic predictors for early and late postprostatectomy PSA failure. Urology 2001;58:400–405.
   PubMed Web of Science ®Google Scholar
• Obuchowski NA. Receiver operating characteristic curves and their use in radiology. Radiology 2003;229:3–8.
   PubMed Web of Science ®Google Scholar
• Obuchowski NA, Lieber ML, Wians FH Jr. ROC curves in clinical chemistry: uses, misuses, and possible solutions. Clin Chem 2004;50:1118–1125.
   PubMed Web of Science ®Google Scholar
• Bonnefoi H, Potti A, Delorenzi M, et al Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy o f the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol 2007;8:1071–1078.
   PubMed Web of Science ®Google Scholar
• Walter SD, Sinuff T. Studies reporting ROC curves of diagnostic and prediction data can be incorporated into meta-analyses using corresponding odds ratios. J Clin Epidemiol 2007;60:530–534.
   PubMed Web of Science ®Google Scholar
• Zou KH, O'Malley AJ, Mauri L. Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models. Circulation 2007;115:654–657.
   PubMed Web of Science ®Google Scholar
• Søreide K. Receiver-operating characteristic curve analysis in diagnostic, prognostic and predictive biomarker research. J Clin Pathol 2009;62:1–5.
   PubMed Web of Science ®Google Scholar
• Langley FA, Buckley CH, Tasker M. The use of ROC curves in histopathologic decision making. Anal Quant Cytol Histol 1985;7:167–173.
   PubMed Web of Science ®Google Scholar
• Obermann EC, Went P, Zimpfer A, et al Expression of minichromosome maintenance protein 2 as a marker for proliferation and prognosis in diffuse large B-cell lymphoma: a tissue microarray and clinico-pathological analysis. BioMed Cent Cancer 2005;5:162.
   Google Scholar
• Zlobec I, Steele R, Terracciano L, et al Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol 2007;60:1112–1116.
   PubMed Web of Science ®Google Scholar
• Brunner A, Prelog M, Verdorfer I, et al EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinomas of the bladder. J Clin Pathol 2008;61:307–310.
   PubMed Web of Science ®Google Scholar
• Adams H, Tzankov A, d'Hondt S, Jundt G, Dirnhofer S, Went P. Primary diffuse large B-cell lymphomas of the bone: prognostic relevance of protein expression and clinical factors. Hum Pathol 2008;39:1323–1330.
   PubMed Web of Science ®Google Scholar
• Adams H, Tzankov A, Lugli A, Zlobec I. New time-dependent approach to analyze the prognostic significance of immunohistochemical biomarkers in colon cancer and diffuse large B-cell lymphoma. J Clin Pathol 2008. published online, DOI 10.1136/jcp.2008.059063.
   Google Scholar
• Meier C, Hoeller S, Bourgau C, et al Recurrent numeric aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas. Mod Pathol 2009;22:476–487.
   PubMed Web of Science ®Google Scholar
• Muenst S, Hoeller S, Dirnhofer S, Tzankov A. Increased PD-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival. Hum Pathol 2009. in press, DOI: 10.1016/j.humpath.2009.03.025.
   Google Scholar
• Hoeller S, Zihler D, Zlobec I, et al BOB.1, CD79a and Cyclin E are the most appropriate markers to discriminate classical Hodgkin lymphoma from primary mediastinal large B-cell lymphoma. Histopathology 2009. in press.
   Google Scholar
• Zellweger T, Günther S, Zlobec I, et al Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer. Int J Cancer 2009;124:2116–2123.
   PubMed Web of Science ®Google Scholar
• Baker SG. The central role of receiver operating characteristic (ROC) curves in evaluating tests for the early detection of cancer. J Nat Cancer Inst 2003;95:511–515.
   PubMed Web of Science ®Google Scholar
• Bewick V, Cheek L, Ball J. Statistics review 13: receiver operating characteristic curves. Critical Care 2004;8:508–512.
   PubMed Web of Science ®Google Scholar
• Perkins NJ, Schisterman EF. The inconsistency of ‘optimal’ cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol 2006;163:670–675.
   PubMed Web of Science ®Google Scholar
• Cook NR. Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve. Clin Chem 2008;54:17–23.
   PubMed Web of Science ®Google Scholar
• Altman DG, Royston P. The cost of dichotomising continuous variables. Br Med J 2006;332:1080.
   PubMed Web of Science ®Google Scholar
• Pepe MS, Zheng Y, Jin Y, Huang Y, Parikh CR, Levy WC. Evaluating the ROC performance of markers for future events. Lifetime Data Anal 2008;14:86–113.
   PubMed Web of Science ®Google Scholar
• Youden WJ. Index for rating diagnostic tests. Cancer 1950;3:32–35.
   PubMed Web of Science ®Google Scholar
• Hilden J, Glasziou P. Regret graphs, diagnostic uncertainty and Youden's Index. Stat Med 1996;15:969–986.
   PubMed Web of Science ®Google Scholar
• Perkins NJ, Schisterman EF. The Youden Index and the optimal cut-point corrected for measurement error. Biometrical J 2005;47:428–441.
   PubMed Web of Science ®Google Scholar
• Schisterman EF, Perkins NJ, Liu A, Bondell H. Optimal cut-point and its corresponding Youden Index to discriminate individuals using pooled blood samples. Epidemiology 2005;16:73–81.
   PubMed Web of Science ®Google Scholar
• Medinger M, Skoda R, Gratwohl A, et al Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status. Br J Haematol 2009;146:150–157.
   PubMed Web of Science ®Google Scholar
• Breiman L, Friedman JH, Olshen RA, et al Classification and Regression Trees. Boca Raton: Chapman & Hall/CRC; 1984.
   Google Scholar
• Riley RD, Sauerbrei W, Altman DG. Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond. Br J Cancer 2009;100:1219–1229.
   PubMed Web of Science ®Google Scholar
• Zlobec I, Lugli A, Baker K, et al Role of APAF-1, E-cadherin and peritumoral lymphocytic infiltration in tumour budding in colorectal cancer. J Pathol 2007;212:260–268.
   PubMed Web of Science ®Google Scholar
• Efron B, Tibshirani RJ. An Introduction to the Bootstrap. Boca Raton, FL: CRC Press; 1998.
   Google Scholar
• Cox DR. Regression models and life-tables. J Royal Stat Soc B Stat Methodol 1972;34:187–220.
   Web of Science ®Google Scholar